{"id":"ly900014","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LY900014 is an ultra-rapid insulin lispro developed using Eli Lilly's proprietary formulation technology to accelerate the onset and peak of insulin action compared to standard insulin lispro. It is designed to more closely match the body's natural postprandial insulin secretion pattern, reducing blood glucose excursions after meals in patients with diabetes.","oneSentence":"LY900014 is a rapid-acting insulin lispro formulation that mimics endogenous insulin by binding to insulin receptors to facilitate glucose uptake and metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:55.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06370715","phase":"PHASE4","title":"A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-04-18","conditions":"Diabetes Mellitus, Type 2","enrollment":150},{"nctId":"NCT05262387","phase":"PHASE1","title":"A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-02-14","conditions":"Diabetes Mellitus, Type 1","enrollment":25},{"nctId":"NCT04605991","phase":"PHASE3","title":"A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-11-04","conditions":"Type 2 Diabetes","enrollment":187},{"nctId":"NCT03952130","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-05-29","conditions":"Type 1 Diabetes Mellitus","enrollment":354},{"nctId":"NCT04585776","phase":"PHASE2","title":"A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-10-30","conditions":"Type 1 Diabetes","enrollment":31},{"nctId":"NCT03952143","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-05-27","conditions":"Type 2 Diabetes Mellitus","enrollment":628},{"nctId":"NCT03740919","phase":"PHASE3","title":"A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-07","conditions":"Type 1 Diabetes Mellitus","enrollment":751},{"nctId":"NCT04049123","phase":"PHASE1","title":"A Study of LY900014 in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-11-18","conditions":"Healthy","enrollment":15},{"nctId":"NCT04276207","phase":"PHASE1","title":"A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-25","conditions":"Diabetes Mellitus, Type 1","enrollment":32},{"nctId":"NCT03830281","phase":"PHASE3","title":"A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-02-14","conditions":"Type 1 Diabetes Mellitus","enrollment":471},{"nctId":"NCT03760640","phase":"PHASE2","title":"A Study of LY900014 in a Medtronic Pump","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-02-18","conditions":"Type1 Diabetes Mellitus","enrollment":42},{"nctId":"NCT03465878","phase":"PHASE1","title":"A Study of LY900014 in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-26","conditions":"Type 1 Diabetes Mellitus","enrollment":56},{"nctId":"NCT02703337","phase":"PHASE1","title":"A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03","conditions":"Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT02703324","phase":"PHASE1","title":"A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03","conditions":"Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT02703350","phase":"PHASE1","title":"A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03","conditions":"Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT03341312","phase":"PHASE1","title":"A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-11-13","conditions":"Diabetes Mellitus, Type 2","enrollment":36},{"nctId":"NCT02770521","phase":"PHASE1","title":"A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-05","conditions":"Healthy","enrollment":23},{"nctId":"NCT03305822","phase":"PHASE1","title":"A Study of LY900014 in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-10-11","conditions":"Diabetes Mellitus, Type 2","enrollment":38},{"nctId":"NCT02525744","phase":"PHASE1","title":"A Study of a New LY900014 Formulation in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT03341299","phase":"PHASE1","title":"A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-11-13","conditions":"Diabetes Mellitus, Type 1","enrollment":36},{"nctId":"NCT02636361","phase":"PHASE1","title":"A Study of Various Formulations of LY900014 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-12","conditions":"Healthy","enrollment":26},{"nctId":"NCT02317575","phase":"PHASE1","title":"A Study of LY900014 Formulations in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-01","conditions":"Healthy Volunteers","enrollment":29},{"nctId":"NCT02752087","phase":"PHASE1","title":"A Study to Compare the Effects of a Test and Reference Formulation of LY900014 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-04","conditions":"Healthy","enrollment":24},{"nctId":"NCT03334448","phase":"PHASE1","title":"A Study to Compare 2 Formulations of LY900014 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-12-04","conditions":"Healthy","enrollment":49},{"nctId":"NCT03056456","phase":"PHASE1","title":"A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-02-23","conditions":"Diabetes Mellitus, Type 1","enrollment":24},{"nctId":"NCT03407118","phase":"PHASE1","title":"A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-02-17","conditions":"Diabetes Mellitus, Type 1","enrollment":31},{"nctId":"NCT03286751","phase":"PHASE1","title":"A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-10-13","conditions":"Diabetes Mellitus, Type 2","enrollment":42},{"nctId":"NCT03214367","phase":"PHASE3","title":"A Study of LY900014 in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-17","conditions":"Type 1 Diabetes Mellitus","enrollment":1392},{"nctId":"NCT03449433","phase":"PHASE1","title":"A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-15","conditions":"Diabetes Mellitus, Type 1","enrollment":80},{"nctId":"NCT03616977","phase":"PHASE1","title":"Study to Compare 2 Formulations of LY900014 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-08-03","conditions":"Healthy","enrollment":69},{"nctId":"NCT03166124","phase":"PHASE1","title":"A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-05-24","conditions":"Diabetes Mellitus, Type 1","enrollment":80},{"nctId":"NCT03232983","phase":"PHASE1","title":"A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-08-14","conditions":"Diabetes Mellitus, Type 2","enrollment":28},{"nctId":"NCT02942654","phase":"PHASE1","title":"A Study of LY900014 Formulation in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-11","conditions":"Healthy","enrollment":32},{"nctId":"NCT03214380","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-14","conditions":"Type 2 Diabetes Mellitus","enrollment":933},{"nctId":"NCT03433677","phase":"PHASE3","title":"A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-02-21","conditions":"Diabetes Type 1","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ultra-Rapid Lispro","Lyumjev"],"phase":"phase_3","status":"active","brandName":"LY900014","genericName":"LY900014","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Biologic","firstApprovalDate":"","aiSummary":"LY900014 is a rapid-acting insulin lispro formulation that mimics endogenous insulin by binding to insulin receptors to facilitate glucose uptake and metabolism. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":20,"withResults":20},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}